Brian A Baldo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2108211/publications.pdf

Version: 2024-02-01

63 papers	1,386 citations	394421 19 h-index	361022 35 g-index
65 all docs	65 docs citations	65 times ranked	1515 citing authors

#	Article	IF	Citations
1	Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies, 2022, 11, 17.	2.5	16
2	Mechanisms of opioid-induced respiratory depression. Archives of Toxicology, 2022, 96, 2247-2260.	4.2	18
3	Drug Allergy. , 2021, , .		6
4	Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Archives of Toxicology, 2021, 95, 2627-2642.	4.2	44
5	Inhibition of platelet-activating factor (PAF)-induced platelet aggregation by fatty acids from human saliva. Platelets, 2021, , 1-8.	2.3	0
6	Biologics: Monoclonal Antibodies for Non-cancer Therapy, Cytokines, Fusion Proteins, Enzymes, and Hormones. , 2021, , 533-593.		1
7	Opioid Analgesic Drugs. , 2021, , 411-438.		1
8	Non-targeted Drugs for Cancer Therapy. , 2021, , 645-682.		0
9	Drugs and Other Agents Used in Anesthesia and Surgery. , 2021, , 315-409.		0
10	The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. British Journal of Anaesthesia, 2020, 124, 44-62.	3.4	61
11	Anaphylaxis to sugammadex-rocuronium inclusion complex: An IgE-mediated reaction due to allergenic changes at the sugammadex primary rim. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1410-1415.e3.	3.8	26
12	Reply to â€œDoes sugammadex have multiple mechanisms for causing anaphylaxis?â€• Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2458-2459.	3.8	0
13	Cephalosporin allergens: Is the cephalosporoyl and R1 side-chain focus too narrow?. Journal of Allergy and Clinical Immunology, 2020, 146, 459-460.	2.9	1
14	Perioperative Reactions to Sugammadex. Current Treatment Options in Allergy, 2020, 7, 43-63.	2.2	6
15	Stability of neuromuscular blocking drugs used for skin testing. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1201-1202.	5.7	1
16	Anaphylaxis caused by sugammadex- rocuronium inclusion complex: What is the basis of the allergenic recognition?. Journal of Clinical Anesthesia, 2019, 54, 48-49.	1.6	9
17	Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Archives of Toxicology, 2018, 92, 2457-2473.	4.2	64
18	Î”â€Myrtoxinâ€Mp1a is a Helical Heterodimer from the Venom of the Jack Jumper Ant that has Antimicrobial, Membraneâ€Disrupting, and Nociceptive Activities. Angewandte Chemie - International Edition, 2017, 56, 8495-8499.	13.8	28

#	Article	IF	Citations
19	Î”â€Myrtoxinâ€Mp1a is a Helical Heterodimer from the Venom of the Jack Jumper Ant that has Antimicrobial, Membraneâ€Disrupting, and Nociceptive Activities. Angewandte Chemie, 2017, 129, 8615-8619.	2.0	1
20	Opioid Analgesic Drugs: Misuse, Toxicity, and Hypersensitivity. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1607-1608.	3.8	5
21	Fusion Proteins. , 2016, , 263-307.		1
22	Enzymes Approved for Therapy. , 2016, , 419-477.		1
23	Approved Biologics Used for Therapy and Their Adverse Effects. , 2016, , 1-27.		1
24	Safety of Biologics Therapy. , 2016, , .		14
25	Monoclonal Antibodies Approved for Cancer Therapy. , 2016, , 57-140.		11
26	Allergenic significance of cephalosporin side chains. Journal of Allergy and Clinical Immunology, 2015, 136, 1426-1428.	2.9	9
27	Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects. BioDrugs, 2015, 29, 31-55.	4.6	65
28	Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety. Drug Safety, 2015, 38, 455-479.	3.2	54
29	Drugs that Act on the Immune System. Side Effects of Drugs Annual, 2014, , 561-590.	0.6	1
30	Side Effects of Cytokines Approved for Therapy. Drug Safety, 2014, 37, 921-943.	3.2	126
31	IgE and Drug Allergy: Antibody Recognition of â€˜Smallâ€™ Molecules of Widely Varying Structures and Activities. Antibodies, 2014, 3, 56-91.	2.5	9
32	Adverse Events to Nontargeted and Targeted Chemotherapeutic Agents. Immunology and Allergy Clinics of North America, 2014, 34, 565-596.	1.9	30
33	Drug Allergy. , 2013, , .		31
34	On the question of the association between immediate hypersensitivity to quinolones and neuromuscular blocking drug sensitization. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 709-710.	3.8	4
35	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer and Metastasis Reviews, 2013, 32, 723-761.	5.9	52
36	Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. OncoImmunology, 2013, 2, e26333.	4.6	145

#	Article	IF	Citations
37	Mechanisms of Hypersensitivity. , 2013, , 37-90.		3
38	Structural determinants of antibiotic allergy. Current Allergy and Asthma Reports, 2001, 1, 23-31.	5.3	13
39	Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects. Journal of Molecular Recognition, 2001, 14, 300-307.	2.1	13
40	Chemistry of drug allergenicity. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 327-335.	2.3	48
41	Flow cytometric analysis of cell killing by the jumper ant venom peptide pilosulin 1. , 1998, 32, 268-273.		17
42	Î²-Lactam drug allergens: Fine structural recognition patterns of cephalosporin-reactive IgE antibodies. Journal of Molecular Recognition, 1996, 9, 287-296.	2.1	57
43	Separation of jumper ant (Myrmecia pilosula) venom allergens: A novel group of highly basic proteins. Electrophoresis, 1995, 16, 804-810.	2.4	12
44	Immunoaffinity analysis of cross-reacting allergens by protein blotting. Electrophoresis, 1993, 14, 917-922.	2.4	6
45	Intra-species cross-reactivity of house dust mite allergens separated by protein blotting and detected by selective elution of mite components and IgE antibodies. Electrophoresis, 1993, 14, 923-925.	2.4	10
46	Measurement of PAF in blood by radioimmunoassay. Journal of Immunological Methods, 1992, 151, 131-138.	1.4	8
47	Stability of platelet activating factor (PAF) in human saliva. Quantitation by radioimmunoassay. Clinica Chimica Acta, 1991, 200, 161-173.	1.1	12
48	Synthesis of a PAF immunogen and production of PAF-specific antibodies. Lipids, 1991, 26, 1130-1135.	1.7	4
49	A specific, sensitive and high-capacity immunoassay for PAF. Lipids, 1991, 26, 1136-1139.	1.7	13
50	Quantitation by radioimmunoassay of PAF in human saliva. Lipids, 1991, 26, 1140-1143.	1.7	12
51	Inhibitor(s) of platelet-activating factor (PAF) in human saliva. Lipids, 1991, 26, 1144-1147.	1.7	16
52	White cypress pine pollen: an important seasonal allergen source in rural Australia. Medical Journal of Australia, 1991, 155, 572-572.	1.7	13
53	Anaphylactoid reactions to narcotic analgesics. Clinical Reviews in Allergy, 1991, 9, 309-318.	1.0	51
54	The specificity of the binding of platelet activating factor (PAF) to anti-PAF antibodies. Journal of Molecular Recognition, 1990, 3, 169-173.	2.1	6

#	Article	IF	Citations
55	A specific, sensitive radioimmunoassay for platelet-activating factor (PAF). Journal of Immunological Methods, 1990, 128, 183-188.	1.4	31
56	Enhanced immunodetection of blotted house dust mite protein allergens on nitrocellulose following blocking with tween 20. Electrophoresis, 1989, 10, 243-249.	2.4	24
57	Acute anaphylactic reactions. Medical Journal of Australia, 1988, 149, 34-38.	1.7	27
58	Comparison of semi-dry and conventional tank-buffer electrotransfer of proteins from polyacrylamide gels to nitrocellulose membranes. Electrophoresis, 1987, 8, 384-387.	2.4	67
59	Characterisation of allergens by protein blotting. Electrophoresis, 1987, 8, 452-463.	2.4	38
60	Atracurium and anaphylaxis. Medical Journal of Australia, 1986, 144, 220-220.	1.7	7
61	Parietaria as a cause of asthma. Medical Journal of Australia, 1984, 140, 511-511.	1.7	16
62	Allergy, allergens and allergen standardization. Medical Journal of Australia, 1984, 141, S5-8.	1.7	1
63	Adverse reactions to alcuronium: An Australian disease?. Medical Journal of Australia, 1983, 1, 630-632.	1.7	17